FDA Investigator Marisol Faberlle
Marisol Faberlle has inspections in 2 countries as of 05 Sep 2022. Marisol Faberlle has collaborated with a combined 1073 experts on various inspections, contributing to compliance and improvement across diverse sectors.
Investigator Details
Number of Inspected Sites:
8
Last Inspection Date:
05 Sep 2022
Investigator Role:
FDA Investigator
Redica ID:
Country:
United States of America,
Netherlands
Co-Investigator(s):
An T Vu,
Anthony A Charity,
Arlene M Badillo,
Barbara Janine Breithaupt,
Bonita S Chester,
Brian R Yaun,
Brooke K Higgins,
CDR Ileana Barreto Pettit,
Dayna I Martinez,
Dennis Cantellops Paite,
Douglas A Campbell,
Elena Karnaukhova, PhD,
Farhana Khan,
Frances L Dejesus,
Frank W Perrella,
Gerardo Z Vazquez,
Hanisol Fabenelle,
Iraida Ortiz,
Jaime E Pares,
James D Planchon,
James P Mcreavey,
Javier O Vega,
Jensel L Guadalupe,
Joan M Cantellops Figueroa,
Jorge L Guadalupe,
Jose Acruz Gonzalez,
Jose I Guadalupe,
Jose R Lopez,
Jose Velez,
Kham Phommachanh,
Kimberley A Hoefen,
Libia M Lugo,
Luis M Burgos Medero,
Marian E Ramirez,
Marianela Aponte Cruz,
Maridalia Torres Irizarry,
Marisal Faberhe,
Marvin D Jones,
Meisha R Sampson,
Meisha Waters,
Myriam M Sosa,
Nicole K Trudel,
Noreen Muniz,
Patrick L Wisor,
Paul L Figarole, Jr,
Reyes Candau Chacon, PhD,
Richard Heath Coats,
Robert J Ham,
State Agency,
Steven C Madzo,
Steven M Weinman,
Susant Hadman,
Tara G Bizjak,
Tara R Gooen,
Terri L Dodds,
Tiffani D Wilson,
Truong Xuan Nguyen (Andy),
Wayne T Smith,
Yumi J Hiramine
Marisol Faberlle's Documents
Publish Date | Document Type | Title |
---|---|---|
October, 2000 | EIR | Merck Sharp & Dohme BV - EIR, 2000-10-25 |
October, 2000 | FDA 483 Response | N.v. Organon - Form 483R, 2000-12-12 |
November, 2000 | FDA 483 Response | Avebe - Form 483R, 2000-11-23 |
October, 2000 | FDA 483 Response | Merck Sharp & Dohme BV - Form 483R, 2000-11-06 |
November, 2000 | FDA 483 | Glucona B.V. - Form 483, 2000-11-01 |
October, 2003 | FDA 483 | Janssen Ortho LLC - Form 483, 2003-10-15 |
October, 2003 | EIR | Janssen Ortho LLC - EIR, 2003-10-15 |
October, 2000 | EIR | N.v. Organon - EIR, 2000-10-20 |
November, 2000 | EIR | Avebe - EIR, 2000-11-01 |
October, 2000 | FDA 483 | Merck Sharp & Dohme BV - Form 483, 2000-10-25 |
October, 2000 | FDA 483 | MSD Organon - Form 483, 2000-10-18 |
October, 2003 | FDA 483 Response | Janssen Ortho LLC - Form 483R, 2003-12-19 |
Experience Redica Systems’ NEW investigator profiles and dashboards
Redica Systems customers get access to over 1,400 FDA Investigator profiles, containing powerful analysis like:
- Total inspections conducted
- 483 rate
- OAI rate
- Warning Letter rate
- Inspections by Industry, Scope, and Inspection Reason
- And much more
Investigator Profiles are not sold as on-demand documents. If you’d like to see one, fill out the form below to connect with our Sales Team and get it in your inbox as little as 24 hours.
![FDA Investigator Profile Icon](https://redica.com/document-store/images/InspectorProfile.png)
Talk to sales to access our investigator profiles
Loading...
Investigator Profiles Are Just the Tip of the Iceberg
Becoming a Redica Systems customer not only provides you with unlimited access to profiles similar to the one above for every current and former FDA Investigator, but also grants you access to:
Inspection Intelligence
- Pre-Approval Inspection (PAI) trends
- The ability to filter nearly any FDA enforcement action by GxP labels like GMP, GCP, etc.
- Latest 483s: see what the trends are across all FDA Investigators
- CFR Heatmap: Citations aggregated by Subpart by Year
Vendor Intelligence
- Full inspection histories for your vendors down to the specific site level
- All of the functionality mentioned above but isolated to just your vendors
Regulatory Intelligence
- Zero in on the trends for a specific agency/regulator (ex. FDA, MHRA, EMA, Health Canada)
- All the latest "Signals" from agencies around the world, segmented by Country, Type (ex. Guidance, Decree...), Category (ex. Rules/Regulations/Guidance, News, Reports...), Theme (ex. Cell and Gene Therapy, AI...), and more